Richard Pulik serves as the Chief Financial Officer at ROIVANT SCIENCES LTD, a biopharmaceutical company focused on developing and commercializing innovative therapies. In his role, Pulik is responsible for overseeing the financial strategy and operations of the company, ensuring its fiscal health and supporting its growth initiatives. His leadership has been instrumental in guiding ROIVANT SCIENCES LTD through various stages of development, from early-stage research to the commercialization of new treatments. Before joining ROIVANT SCIENCES LTD, Pulik amassed a wealth of experience in the financial sector, particularly within the healthcare industry. He held several high-level positions at major pharmaceutical companies, where he honed his skills in financial management, strategic planning, and corporate governance. Pulik's expertise in navigating complex financial landscapes and his ability to drive profitability have been key factors in his success. His strategic vision and meticulous attention to detail have earned him a reputation as a trusted leader in the field. Among his notable achievements, Pulik has been recognized for his role in securing significant funding for ROIVANT SCIENCES LTD, enabling the company to advance its research and development efforts. His strategic financial planning has also been crucial in facilitating successful partnerships and acquisitions, further strengthening the company's position in the competitive biopharmaceutical market. Under Pulik's guidance, ROIVANT SCIENCES LTD continues to thrive, driven by a commitment to innovation and excellence in healthcare.